Improving the detection of SARS-CoV-2 in point-of-care settings: a real-world performance evaluation of the Cobas SARS-CoV-2 nucleic acid test for use on the Cobas Liat System

  1. Myrto Bolanaki
  2. Martin Möckel
  3. Christopher Dodoo
  4. Karen Gilliam
  5. Elissa Robbins
  6. D Jane Hata
  7. Bruce White
Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background

There is a need to confirm the clinical performance of point-of-care (POC) testing for severe acute respiratory coronavirus 2 (SARS-CoV-2) in emergency departments and time-sensitive outpatient settings. This study aimed to compare the clinical performance of the Cobas ® SARS-CoV-2 nucleic acid test for use on the Cobas Liat System (POC SARS- CoV-2) with the Cobas SARS-CoV-2 Qualitative Assay for use on the Cobas 6800/8800 System (68/8800) when used to detect SARS-CoV-2 infection in individuals at POC settings.

Methods

This prospective, two-site, non-interventional study, conducted in the US and Germany, collected fresh POC nasopharyngeal samples according to local procedures for upper respiratory swab sampling. Pairwise agreement was evaluated by estimating positive, negative, and overall percent agreement (PPA, NPA, and OPA, respectively) between POC SARS-CoV-2 and 68/8800 assays. Site-specific analyses were also conducted.

Findings

Overall, 317 evaluable samples were collected from March 30 to July 2023 (US site) and from November 7, 2023 to April 4, 2024 (German site). Relative to 68/8800, POC SARS-CoV-2 had a PPA of 98.8% (169/171) and an NPA of 90.4% (132/146). The OPA was 95.0%. Site-specific analyses were broadly comparable to the overall results, although enrichment for positive samples at the US site resulted in a PPA and NPA of 98.6% (139/141) and 55.6% (5/9), respectively.

Interpretation

POC SARS-CoV-2 used in real-world POC settings showed good overall clinical performance relative to 68/8800, a widely used and accurate laboratory-based test, for detecting SARS-CoV-2. Efficient POC testing will help improve the timely management of SARS-CoV-2 infections.

Key points

  • There are limited clinical studies evaluating the clinical performance of SARS-CoV-2 assays in real-world populations

  • The Cobas ® SARS-CoV-2 nucleic acid test for use on the Cobas Liat System showed good clinical performance relative to a widely used laboratory-based test for detecting SARS-CoV-2 at two point-of-care hospital sites.

  • Efficient point-of-care testing will help improve the timely management of SARS- CoV-2 infections

Article activity feed

  1. Version published to 10.1101/2025.02.28.25323093v1 on medRxiv